Tiagabina: aspectos recientes y recomendaciones para su dosificación
Introduction. Tiagabine causes GABA to remain in the synapses longer since it inhibits the protein GAT-1, which normally transports GABA for uptake by the glia and neurones. Development. With its advantageous pharmacokinetics, it is particularly effective in patients with complex partial crises, and leads to complete control in 53% of new patients treated with tiagabine alone. Side effects are infrequent, especially when treatment with the drug is started gradually and increased weekly. The lowest effective dose has been found to be 15 mg/day. The usual maintenance dose is between 15 and 30 mg/day taken divided into 2 or 3 doses per day
Desarrollo Con una farmacocinética favorable, se muestra especialmente eficaz en pacientes con crisis parciales complejas, consiguiendo el control total de dichas crisis en el 53% de pacientes nuevos con tiagabina en monoterapia. Los efectos adversos son poco frecuentes, especialmente cuando se introduce el fármaco lentamente, con incrementos semanales de la dosis, debiendo considerarse 15 mg/día la dosis mínima eficaz, y entre 15 y 30 mg/día la dosis habitual de mantenimiento, repartida en 2 o 3 dosis diarias